Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 12:32PM ET
4.56
Dollar change
-0.26
Percentage change
-5.39
%
IndexRUT P/E- EPS (ttm)-0.28 Insider Own5.31% Shs Outstand58.31M Perf Week-7.13%
Market Cap265.89M Forward P/E28.50 EPS next Y0.16 Insider Trans-0.23% Shs Float55.21M Perf Month-12.14%
Income-16.39M PEG- EPS next Q-0.11 Inst Own76.72% Short Float5.84% Perf Quarter-7.32%
Sales190.86M P/S1.39 EPS this Y-891.67% Inst Trans1.35% Short Ratio5.07 Perf Half Y-23.87%
Book/sh9.28 P/B0.49 EPS next Y150.53% ROA-2.55% Short Interest3.22M Perf Year21.28%
Cash/sh6.45 P/C0.71 EPS next 5Y36.10% ROE-3.02% 52W Range3.46 - 6.75 Perf YTD8.06%
Dividend Est.- P/FCF- EPS past 5Y-37.98% ROI-3.00% 52W High-32.44% Beta0.76
Dividend TTM- Quick Ratio4.84 Sales past 5Y1.11% Gross Margin90.22% 52W Low31.79% ATR (14)0.20
Dividend Ex-Date- Current Ratio4.85 EPS Y/Y TTM-236.47% Oper. Margin-19.64% RSI (14)36.68 Volatility3.17% 3.90%
Employees203 Debt/Eq0.01 Sales Y/Y TTM-9.91% Profit Margin-8.59% Recom1.67 Target Price12.17
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-3908.33% Payout0.00% Rel Volume2.15 Prev Close4.82
Sales Surprise-3.08% EPS Surprise42.57% Sales Q/Q22.76% EarningsNov 06 AMC Avg Volume634.93K Price4.56
SMA20-8.75% SMA50-5.52% SMA200-8.99% Trades Volume672,565 Change-5.39%
Date Action Analyst Rating Change Price Target Change
Oct-31-24Initiated H.C. Wainwright Buy $18
Jul-11-24Initiated Cantor Fitzgerald Overweight $11
Feb-25-22Downgrade Jefferies Buy → Hold $24 → $12
May-12-21Initiated BofA Securities Buy $22
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Nov-12-24 04:58PM
Nov-07-24 02:21AM
Nov-06-24 04:12PM
04:02PM
Nov-01-24 02:05PM
12:27PM Loading…
Oct-31-24 12:27PM
Oct-30-24 04:30PM
Oct-15-24 08:30AM
Oct-14-24 12:08PM
10:56AM
10:37AM
08:19AM
Sep-20-24 07:28AM
06:12AM
Sep-19-24 05:20PM
07:00AM Loading…
07:00AM
Sep-11-24 05:00PM
Sep-04-24 05:13PM
Aug-29-24 04:30PM
Aug-01-24 08:49AM
Jul-31-24 04:06PM
04:01PM
Jul-26-24 09:19AM
Jul-01-24 08:01AM
Jun-28-24 06:53AM
Jun-21-24 07:00AM
Jun-19-24 08:48PM
Jun-13-24 09:00PM
10:02AM
Jun-07-24 06:02AM
09:24AM Loading…
Jun-06-24 09:24AM
08:00AM
07:38AM
May-30-24 05:20PM
04:48PM
May-29-24 02:17PM
May-24-24 04:46PM
May-16-24 11:24AM
06:22AM
May-15-24 01:04PM
08:45AM
May-10-24 03:24PM
May-09-24 12:37PM
06:43AM
03:38AM
May-08-24 08:58PM
04:10PM
04:01PM
May-07-24 11:33AM
11:16AM
09:22AM
09:10AM
09:00AM
Apr-30-24 04:30PM
Apr-25-24 10:45AM
09:00AM
08:05AM
Apr-24-24 06:00PM
01:58PM
Apr-22-24 07:13PM
04:11PM
11:37AM
10:09AM
Apr-19-24 01:06PM
Apr-18-24 09:44AM
09:00AM
Apr-17-24 02:29PM
11:53AM
10:21AM
09:11AM
09:02AM
08:32AM
06:30AM
Apr-15-24 06:00PM
Apr-10-24 06:15PM
Apr-04-24 07:52AM
Apr-03-24 12:02PM
10:48AM
10:00AM
Apr-02-24 06:10PM
Mar-07-24 10:47AM
Mar-06-24 11:55PM
07:00AM
Feb-14-24 04:22AM
Feb-12-24 12:20PM
Feb-08-24 09:38AM
07:06AM
Feb-07-24 05:02PM
04:26PM
04:02PM
Feb-05-24 08:00AM
Jan-31-24 04:30PM
09:00AM
Jan-30-24 12:35PM
01:02AM
Jan-29-24 07:00PM
Jan-25-24 10:05PM
01:07PM
Jan-23-24 09:15AM
Jan-19-24 03:56PM
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mitchell Stephen RayDirectorNov 14 '24Sale5.175,00025,86344,857Nov 18 05:45 PM
Mitchell Stephen RayDirectorNov 14 '24Proposed Sale5.405,00027,000Nov 14 04:10 PM
Moran Kevin PatrickSVP, CFO & TreasurerJul 29 '24Sale5.922,25113,327228,763Jul 29 05:24 PM
Moran Kevin PatrickOfficerJul 29 '24Proposed Sale5.922,25113,327Jul 29 05:21 PM
Williams TimothySVP & General CounselMar 05 '24Sale4.188,94137,396196,825Mar 06 04:50 PM
Williams TimothySVP & General CounselMar 04 '24Sale4.418,14735,917205,766Mar 06 04:50 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 05 '24Sale4.219,22938,830129,789Mar 06 04:48 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 04 '24Sale4.417,49833,091139,018Mar 06 04:48 PM
Polymeropoulos Mihael HristosPresident and CEOMar 04 '24Sale4.2430,884131,0661,896,018Mar 06 04:47 PM
Polymeropoulos Mihael HristosPresident and CEOMar 05 '24Sale4.1324,288100,2731,871,730Mar 06 04:47 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 05 '24Sale4.208,90237,411231,014Mar 06 04:46 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 04 '24Sale4.485,79825,982239,916Mar 06 04:46 PM
Birznieks GuntherSVP, Business DevelopmentMar 04 '24Sale4.308,72737,495322,253Mar 06 04:46 PM
Birznieks GuntherSVP, Business DevelopmentMar 05 '24Sale4.138,68435,884313,569Mar 06 04:46 PM